Login to Your Account

Promise of PCSK9 Plays Out

Regeneron, Sanofi: First Results from Cholesterol Phase III Look Solid

By Randy Osborne
Staff Writer

Wednesday, October 16, 2013

Favorable topline data from Regeneron Pharmaceuticals Inc. and partner Sanofi SA’s first of a dozen Phase III trials with alirocumab for high cholesterol gave cause for encouragement, but investors must wait for full details regarding the results, as well as adverse events (AEs).

These, along with specifics regarding auto-injectors, will be important in comparing Amgen’s Phase III-stage hyperlipidemia compound which, like alirocumab, is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription